SCHEMBL7986517

SCHEMBL7986517

CN(CC1CCN(C(=O)OC(C)(C)C)CC1)C(=O)C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
LIMK2 P53671 1/20 0.48
GPR119 Q8TDV5 8/20 0.47
HPGD P15428 1/20 0.45
KDM4E B2RXH2 1/20 0.44
PKM P14618 1/20 0.44
RECQL P46063 1/20 0.43
EPHX1 P07099 1/20 0.43
USP2 O75604 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
FAAH O00519 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2997902 0.85 LIMK2 (0.51) LIMK2GPR119HPGDKDM4EPKM
SCHEMBL6403145 0.84 KDM4E (0.43) LIMK2GPR119HPGDKDM4EPKM
SCHEMBL1401260 0.84 HPGD (0.53) LIMK2GPR119HPGDKDM4EPKM
SCHEMBL5570674 0.83 HPGD (0.51) LIMK2GPR119HPGDKDM4EPKM
SCHEMBL30085213 0.80 KDM4E (0.48) LIMK2GPR119HPGDKDM4EPKM
SCHEMBL2424909 0.79 HPGD (0.48) GPR119HPGDRECQLEPHX1USP2
SCHEMBL25580911 0.79 HPGD (0.48) LIMK2GPR119HPGDKDM4EPKM
SCHEMBL22318555 0.78 CTSK (0.36) HPGD
SCHEMBL22318556 0.78 CTSK (0.36) HPGD
SCHEMBL27391556 0.78 HPGD (0.50) LIMK2GPR119HPGDKDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6235731-B1 REDUCING BLOOD LIPIDS, SUGARS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-05-22 US disclosed
EP-0915888-A1 FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS Takeda Chemical Industries, Ltd. (JP) 1999-05-19 EP disclosed
WO-1997040051-A1 FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-10-30 WO disclosed